Francis Reynolds Net Worth

The estimated Net Worth of Francis Reynolds is at least $12.7 Million dollars as of 7 May 2014. Francis Reynolds owns over 50,000 units of InVivo Therapeutics Corp stock worth over $2,894,694 and over the last 14 years Francis sold NVIV stock worth over $9,762,909.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Francis Reynolds NVIV stock SEC Form 4 insiders trading

Francis has made over 139 trades of the InVivo Therapeutics Corp stock since 2011, according to the Form 4 filled with the SEC. Most recently Francis sold 50,000 units of NVIV stock worth $60,000 on 7 May 2014.

The largest trade Francis's ever made was selling 270,000 units of InVivo Therapeutics Corp stock on 10 April 2012 worth over $610,200. On average, Francis trades about 28,273 units every 6 days since 2011. As of 7 May 2014 Francis still owns at least 9,045,920 units of InVivo Therapeutics Corp stock.

You can see the complete history of Francis Reynolds stock trades at the bottom of the page.

What's Francis Reynolds's mailing address?

Francis's mailing address filed with the SEC is C/O INVIVO THERAPEUTICS HOLDINGS CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at InVivo Therapeutics Corp

Over the last 14 years, insiders at InVivo Therapeutics Corp have traded over $11,891,061 worth of InVivo Therapeutics Corp stock and bought 364,908 units worth $191,940 . The most active insiders traders include Francis Reynolds, Robert Langer, and Sean F. Moran. On average, InVivo Therapeutics Corp executives and independent directors trade stock every 24 days with the average trade being worth of $10,438. The most recent stock trade was executed by Brice Foose on 5 February 2023, trading 330,000 units of NVIV stock currently worth $122,100.

What does InVivo Therapeutics Corp do?

about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi

Complete history of Francis Reynolds stock trades at InVivo Therapeutics Corp

InVivo Therapeutics Corp executives and stock owners

InVivo Therapeutics Corp executives and other stock owners filed with the SEC include:

• Richard Toselli,
  President, Chief Executive Officer, Director, Chief Medical Officer
• Dr. Richard M. Toselli,
  Pres, CEO, Chief Medical Officer & Director
• Richard Christopher,
  Chief Financial Officer
• Richard C. Christopher,
  CFO & Treasurer
• C. Ann Merrifield,
  Non-Executive Independent Chairman of the Board
• Robert Rosenthal,
  Independent Director
• Richard Roberts,
  Independent Director
• Christina Morrison,
  Independent Director
• Daniel Marshak,
  Independent Director
• Dr. Louis Vaickus FACP, M.D.,
  Consultant
• Heather Hamel,
  VP of Legal Affairs & Bus. Devel. and Corp. Sec.
• William D'Agostino PE,
  Sr. VP of Operations
• Dr. Joseph Philip Vacanti,
  Co-Founder
• Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
  Co-Founder & Member of Scientific Advisory Board
• Tamara L Joseph,
  SVP, General Counsel
• Christopher Mc Nulty,
  Chief Financial Officer
• Thomas R Ulich,
  Chief Scientific Officer
• Masuoka K. Lorianne,
  Chief Medical Officer
• Jeffrey S. Hatfield,
  Director
• Steven F Mcallister,
  Chief Financial Officer
• Kenneth Di Pietro,
  Director
• Pamela J Stahl,
  Chief Commercial Officer
• Mark D Perrin,
  CHIEF EXECUTIVE OFFICER
• John A Jr Mccarthy,
  Director
• Bob Rosenthal,
  Director
• Brice Foose,
  10% owner
• Brian Hess,
  Chief Technology Officer
• Sean F. Moran,
  Acting Chief Financial Officer
• Gregory D Perry,
  Interim CFO
• Francis Reynolds,
  CEO, CFO
• Michael J Astrue,
  INTERIM CEO
• Adam K Stern,
  Director
• Robert Langer,
  10% owner
• Edward Wirth,
  Chief Science Officer
• George Nolen,
  Director
• Heather Hamel,
  Chief Legal Officer and GC